Quillivant ER | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,747 results for “Quillivant ER”

Trials

View all 1324 →

Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

45 participants · First posted May 20, 2009

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

36 participants · First posted Oct 2, 2014

Active, not recruiting

Evaluating Treatment of ADHD in Children With Down Syndrome

100 participants · First posted Jan 7, 2020

Drugs

View all 180 →

ER-37328

ER-34122

ER-35745

Organizations

Aytu BioPharma

湖南尔康制药股份有限公司

Arvinas

United States

News

View all 239 →

Health Canada Approves Dyanavel XR Extended-Release Amphetamine for ADHD Treatment in Adults and Children

Camizestrant Shows Superior Progression-Free Survival Compared to Fulvestrant in ER+, HER2- Breast Cancer

Promius Pharma Advances Minocycline Hydrochloride ER Development for Rosacea Treatment

Page 1 of 175